WO2018221543A1 - ヘテロシクリデンアセトアミド誘導体の結晶 - Google Patents
ヘテロシクリデンアセトアミド誘導体の結晶 Download PDFInfo
- Publication number
- WO2018221543A1 WO2018221543A1 PCT/JP2018/020634 JP2018020634W WO2018221543A1 WO 2018221543 A1 WO2018221543 A1 WO 2018221543A1 JP 2018020634 W JP2018020634 W JP 2018020634W WO 2018221543 A1 WO2018221543 A1 WO 2018221543A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crystal
- pain
- type
- present
- crystals
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present invention is an excellent Transient Receptor Potential Vanilloid 1 (hereinafter referred to as “TRPV1”) antagonistic action, and is one of heterocyclideneacetamide derivatives useful as a preventive and / or therapeutic agent for pain and the like.
- TRPV1 Transient Receptor Potential Vanilloid 1
- compound ( 1) a method for producing the crystals, and a pharmaceutical composition containing the crystals.
- TRPV1 capsaicin receptor
- the TRP family is similar in structure, has a 6-transmembrane domain, and has an N-terminal side and a C-terminal side in the cell.
- TRPV1 causes cations such as calcium ions and sodium ions to flow into cells in response to capsaicin stimulation, acid (pH 6.0 or lower), heat (43 ° C. or higher), or high osmotic pressure. Therefore, a significant contribution to the neural excitation of TRPV1 was assumed from the expression site and the action of capsaicin. Furthermore, the contribution of TRPV1 to the living body has been clarified from a lot of published information. In particular, mice lacking TRPV1 (TRPV1 knockout mice) do not show increased heat sensitivity due to neuropathic pain.
- Non-Patent Document 2 Freund's ⁇ ⁇ ⁇ Advantant (CFA) -induced inflammatory pain model suppresses edema
- Non-Patent Document 3 the previously reported desensitization effect by TRPV1 agonist is a neuropathic pain model or inflammatory pain model Involvement of TRPV1 in pain has been suggested from showing an analgesic effect.
- TRPV1 which is sometimes referred to as a capsaicin receptor, is known as a target for treating pain, particularly pain such as acute pain, chronic pain, neuropathic pain, and visceral pain.
- TRPV1 is stimulated by vanilloids such as capsaicin, heat, protons, and hyperosmolarity, and plays a central role in pain generation.
- vanilloids such as capsaicin, heat, protons, and hyperosmolarity
- it is also important for a number of additional physiological and pathophysiological processes, such as migraine, depression, neurodegenerative diseases, cognitive impairment, anxiety, epilepsy, cough, diarrhea, pruritus.
- Many studies have been conducted as suitable targets for treating diseases or disorders such as eye pain, inflammation, cardiovascular disorders, eating disorders, medication dependence, medication misuse, and urinary incontinence.
- Polymorph means that the substance has two or more crystal forms (crystal structures). Different crystal forms of a particular substance are also called “polymorphs”. “Polymorphism” generally results in different atomic arrangements in the crystal lattice of various polymorphs by changing the conformation or being affected by intermolecular or intramolecular interactions (particularly hydrogen bonding). It is reflected. On the other hand, the external shape of the substance as a whole is called “form”, which represents the external shape and the existence surface of the crystal regardless of the internal structure. The crystals may exhibit various forms depending on various conditions (for example, growth rate, stirring method (speed, temperature), presence of impurities, etc.).
- Polymorphs of a substance can have different crystal lattice energies, so that in the solid state the polymorphs have different physical properties (eg shape, density, melting point, color, stability, solubility, dissolution rate, etc. ) May be indicated.
- the previous physical properties are the stability, solubility, and bioavailability (in vivo absorption, drug action, etc.) of specific polymorphs used in medicines or pharmaceutical compositions, and the shelf life of medicines. In some cases, it may affect formulation characteristics, processing characteristics, and the like.
- Polymorphism induces higher or lower biological activity compared to the intrinsic activity in that the rate of absorption in the body is different.
- Pharmacological polymorphs of pharmaceuticals may have polymorphic rearrangement during the production process or storage process due to the presence of multiple polymorphs.
- a polymorph exhibits more thermodynamic stability than other polymorphs, it may be more suitable than other polymorphs during formulation preparation. Become one.
- type I crystals are thermodynamically stable, and in various stability tests (long-term storage test, accelerated test) and photostability test). It was stable, and in particular, it showed excellent stability in a photostability test. Therefore, it was found that it can be satisfied as a pharmaceutical raw material, and the present invention was completed based on these findings.
- the type I crystal of the compound (1) of the present invention is a compound having a TRPV1 antagonistic action, and has an action of improving a disease (for example, pain or the like) in which TRPV1 is involved by antagonizing TRPV1.
- a pharmaceutical composition containing the type I crystal of compound (1) of the present invention as an active ingredient is expected as a prophylactic and / or therapeutic agent for diseases involving TRPV1.
- the type I crystal of the compound (1) of the present invention is a compound having a TRPV1 antagonistic action, has low toxicity and is useful as a pharmaceutical product.
- the type I crystal of the compound (1) of the present invention is preferably thermodynamically stable, prevents the transformation of the crystal polymorph in the pharmaceutical production process, and retains the quality of the drug substance or drug. Is possible.
- Speaking of having storage stability it is preferably chemically and physically stable and has no hygroscopicity, so that the quality of the drug substance is maintained within the specifications for a long period of time, It can be easily processed into pharmaceutical products and can be used in pharmaceutical preparations.
- the method for producing the type I crystal of the compound (1) of the present invention is preferably a simple method, and can be used industrially because the type I crystal can be supplied with good yield, high purity and good reproducibility. Is possible. Since the type I crystal of the compound (1) of the present invention is excellent in at least one characteristic selected from the group consisting of storage stability, light stability, thermodynamic stability, etc., it has excellent stability and the like. It is possible to provide a pharmaceutical composition.
- FIG. 1 is a powder X-ray diffraction pattern of type I crystal of the compound (1) in (Example 1).
- FIG. 2 is a photomicrograph of type I crystal of compound (1) in (Example 1).
- FIG. 3 shows FT-IR spectrum data of the type I crystal of the compound (1) in (Example 1).
- FIG. 4 shows DSC thermal analysis data of the type I crystal of the compound (1) of (Example 1).
- FIG. 5 is a powder X-ray diffraction pattern of a type II crystal of compound (1) in (Example 3).
- FIG. 6 is a micrograph of a type II crystal of compound (1) in (Example 3).
- FIG. 7 is FT-IR spectrum data of the type II crystal of the compound (1) in (Example 3).
- FIG. 8 shows DSC thermal analysis data of the type II crystal of compound (1) in (Example 3).
- FIG. 9 is a powder X-ray diffraction pattern of type III crystal of compound (1) in (Exa
- the present invention relates to (E) -2- (7-trifluoromethylchroman-4-ylidene) -N-((7R) -7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) acetamide
- the present invention relates to a type I crystal of (compound (1)), a method for producing the crystal, and a pharmaceutical composition containing the crystal. Moreover, it is related with the manufacturing method of the pharmaceutical composition containing the said crystal
- the present invention includes the following embodiments [1] to [31].
- the crystal according to any one of the embodiments [1] to [14] is referred to as “(E) -2- (7-trifluoromethylchroman-4-ylidene) -N of the present invention”.
- the crystal according to any one of the embodiments [1] to [6] may be referred to as “type I crystal of the present invention”.
- the crystal according to any one of Embodiments [7] to [11] may be referred to as “Type II crystal of the present invention”.
- the crystal according to any one of embodiments [12] to [14] may be referred to as “the type III crystal of the present invention”.
- the diffraction angle (2 ⁇ ) by powder X-ray diffraction is about 7.9, about 8.9, about 10.3, about 12.0, about 15 .8, about 16.4, about 17.2, about 17.6, about 18.3, about 19.5, about 19.9, about 20.8, about 21.6, about 23.9, about 24 .6, about 25.0, about 26.3, about 26.7, about 27.7, about 28.6, about 29.5, about 31.4, about 32.4, about 33.2, about 33 (E) -2- (7-trifluoromethylchroman-4-ylidene) -N-((7R) -7-hydroxy-5,6 having characteristic peaks at .8 and about 34.8 (°) , 7,8-tetrahydronaphthalen-1-yl) acetamide crystals.
- the second embodiment of the present invention is characterized by (E) -2- (7-trifluoromethylchroman-4-ylidene) -N-((7R ) -7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) acetamide.
- a third aspect of the present invention is the (E) -2- (7-trifluoro) having the diffraction angle (2 ⁇ ) and relative intensity (%) shown in Table 2 or Table 3 in powder X-ray diffraction. It is a type I crystal of methylchroman-4-ylidene) -N-((7R) -7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) acetamide.
- a fourth aspect of the present invention is characterized in that (E) -2- (7-trifluoromethylchroman-), wherein the differential scanning calorimetry (DSC measurement) extrapolation melting point starting temperature is 232 ° C.
- DSC measurement differential scanning calorimetry
- 4-Ilidene) -N-((7R) -7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) acetamide crystals preferably the above embodiment [1] none embodiment [3] It is a type I crystal given in any 1 aspect of these.
- the fifth aspect of the present invention is characterized by the (E) -2- (7-triangle) characterized by the FT-IR spectrum diagram shown in FIG. 3 and / or the data value (cm ⁇ 1 ) shown in Table 4.
- a sixth aspect of the present invention is the type I crystal according to any one of the aspects [1] to [5] in the form of needle crystals.
- the diffraction angle (2 ⁇ ) by powder X-ray diffraction is about 10.5, about 12.2, about 12.7, about 16.1, about 17.1, (E) -2- (7-trifluoromethylchroman-4- having characteristic peaks at 18.4, about 19.1, about 20.6, about 22.4, and about 23.8 (°) Iridene) -N-((7R) -7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) acetamide type II crystals.
- the eighth embodiment of the present invention is characterized by (E) -2- (7-trifluoromethylchroman-4-ylidene) -N-((7R ) -7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) acetamide type II crystals.
- a ninth aspect of the present invention provides (E) -2- (7-trifluoromethylchroman-) having a diffraction angle (2 ⁇ ) and a relative intensity (%) shown in Table 5 in powder X-ray diffraction. It is a type II crystal of 4-ylidene) -N-((7R) -7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) acetamide.
- the tenth aspect of the present invention is characterized by the (E) -2- (7-triangle) characterized by the FT-IR spectrum diagram shown in FIG. 7 and / or the data value (cm ⁇ 1 ) shown in Table 6.
- An eleventh aspect of the present invention is the type II crystal according to any one of the aspects [7] to [10], which is in the form of a columnar crystal.
- the diffraction angle (2 ⁇ ) by powder X-ray diffraction is about 6.9, about 13.0, about 16.6, about 17.6, about 19.9, about (E) -2- (7-trifluoromethyl) having characteristic peaks at 20.6, about 21.3, about 22.2, about 24.0, about 27.2 and about 27.8 (°) It is a type III crystal of chroman-4-ylidene) -N-((7R) -7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) acetamide.
- the thirteenth aspect of the present invention is characterized by (E) -2- (7-trifluoromethylchroman-4-ylidene) -N-((7R) -7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) acetamide type III crystals.
- a fifteenth aspect of the present invention is the process for producing a type I crystal according to any one of the above aspects [1] to [6], wherein (E) -2- (7-tri Fluoromethylchroman-4-ylidene) -N-((7R) -7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) acetamide with alcohol solvent or alcohol solvent and acetone A step of obtaining crystals by dissolving with heating using a solvent selected from solvents, adding water under heating and stirring, and then allowing the mixed solution containing water to cool to room temperature under stirring, (E) -2- (7-trifluoromethylchroman-4-ylidene) -N-((7R) -7-hydroxy-5,6 according to any one of embodiments [1] to [6] , 7,8-Tetrahydronaphthalene- - yl) is a manufacturing method of I-form crystals of acetamide.
- the solvent in the embodiment [15] is preferably a mixed solvent of an alcohol solvent and acetone.
- the alcohol solvent in the embodiment [15] or the embodiment [15-1] is preferably methanol, ethanol, or 2-propanol, more preferably methanol or ethanol, and still more preferably. Ethanol.
- a part of the mixed solvent to be used may be mixed with the water to be used.
- the mixed solvent: water 20:10
- the mixed solvent 15 may be heated and dissolved using the mixed solvent 15, and the mixed solvent 5 and the water 10 may be appropriately mixed and used.
- the amount of the mixed solvent used is about 10 mL with respect to 1 g of the solid amount of the compound to be dissolved.
- the water in the production method according to any one of the embodiments [15] to [15-3] is gradually added without adding all at once.
- the dropping speed is not particularly limited.
- the cooling time to room temperature is not particularly limited as long as the temperature of the solvent sufficiently returns to room temperature.
- a sixteenth aspect of the present invention is the method for producing a type II crystal according to any one of the above aspects [7] to [11], wherein (E) -2- (7-tri Fluoromethylchroman-4-ylidene) -N-((7R) -7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) acetamide is converted to an ester solvent, an alcohol solvent, or an ester solvent
- a method according to any one of Aspects [7] to [11] comprising a step of dissolving at room temperature in a solvent selected from a mixed solvent of alcohol and an alcohol solvent and then concentrating under reduced pressure to obtain crystals.
- a seventeenth aspect of the present invention is the method for producing a type III crystal according to any one of the above aspects [12] to [14], wherein (E) -2- (7-tri Fluoromethylchroman-4-ylidene) -N-((7R) -7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) acetamide is dissolved in a polar solvent at room temperature. (E) -2 according to any one of the above embodiments [12] to [14], which comprises a step of adding a mixed solvent at room temperature with stirring, or a step of dissolving in heat in isopropanol and allowing to cool.
- This is a method for producing a type III crystal of-(7-trifluoromethylchroman-4-ylidene) -N-((7R) -7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) acetamide .
- An eighteenth aspect of the present invention is a pharmaceutical composition comprising the crystal according to any one of the aspects [1] to [14] as an active ingredient.
- the crystal in the aspect [18] is preferably the type I crystal according to any one of the aspects [1] to [6].
- a nineteenth aspect of the present invention includes acute pain, chronic pain, neuropathic pain, postherpetic neuralgia, trigeminal neuralgia, back pain, pain after spinal cord injury, lower limb pain, causalgia, diabetic neuralgia, edema, burns, Sprain, pain due to fracture, pain after surgery, periarthritis, osteoarthritis, arthritis, rheumatoid arthritis pain, inflammatory pain, cancer pain, migraine, headache, toothache, neuralgia, muscle pain, hyperalgesia, Pain due to angina or menstruation, neuropathy, nerve damage, neurodegeneration, chronic obstructive pulmonary disease (COPD), asthma, airway hyperresponsiveness, wheezing, cough, rhinitis, inflammation of the mucous membrane of the eyes, neurological skin disease, psoriasis, Eczema inflammatory skin disease, edema, allergic disease, gastroduodenal ulcer, ulcerative colitis, irritable colon, Crohn's disease
- treating refers to the progression of “disease” or the recovery or alleviation of one or more “diseases”. Or it means to suppress.
- prevent means preventing the onset of the “disease” or any symptoms related to the “disease” depending on the condition of the patient. Also includes prevention of “disease” and reducing severity of “disease” or any symptom thereof before onset
- a twentieth aspect of the present invention is a pharmaceutical composition for treating at least one disease according to the nineteenth aspect of the present invention, in an amount effective to antagonize TRPV1.
- a pharmaceutical composition comprising, as an active ingredient, the crystal according to any one of aspects [1] to [14].
- the crystal in the aspect [20] is preferably the type I crystal according to any one of the aspects [1] to [6].
- a twenty-first aspect of the present invention is the disease according to the nineteenth aspect of the present invention, comprising the crystal according to any one of the above-described aspects [1] to [14] as an active ingredient. It is a prophylactic and / or therapeutic agent for at least one disease selected from the group consisting of:
- the crystals in the above embodiments [21] and [21-1] are preferably the type I crystals described in any one of the above embodiments [1] to [6].
- a twenty-second aspect of the present invention is the disease according to the nineteenth aspect of the present invention, comprising the crystal according to any one of the above-described aspects [1] to [14] as an active ingredient. It is a therapeutic agent for at least one disease selected from the group consisting of:
- [22-1] In the above embodiment [22], preferably, it is a therapeutic agent for a disease of pain, comprising the crystal according to any one of the above embodiments [1] to [14] as an active ingredient.
- the crystals in the above embodiments [22] and [22-1] are preferably type I crystals according to any one of the above embodiments [1] to [6].
- a twenty-third aspect of the present invention is the prevention of a disease associated with TRPV1, comprising the crystal according to any one of the above-described aspects [1] to [14] as an active ingredient. Agent and / or therapeutic agent.
- the crystal in the aspect [23] is preferably the type I crystal according to any one of the aspects [1] to [6].
- a twenty-fourth aspect of the present invention is a treatment for a disease associated with TRPV1, characterized by containing the crystal according to any one of the above-mentioned aspects [1] to [14] as an active ingredient. It is an agent.
- the crystal in the aspect [24] is preferably the type I crystal according to any one of the aspects [1] to [6].
- a twenty-fifth aspect of the present invention is a pharmaceutical composition comprising the crystal according to any one of the above aspects [1] to [14] as an active ingredient, which is a TRPV1 antagonist.
- the crystal in the aspect [25] is preferably the type I crystal according to any one of the aspects [1] to [6].
- a twenty-sixth aspect of the present invention is the use of the crystal according to any one of the above aspects [1] to [14] as a pharmaceutical composition.
- the crystal in the embodiment [26] is preferably the type I crystal described in any one of the embodiments [1] to [6].
- a twenty-seventh aspect of the present invention is the use of the crystal according to any one of the above aspects [1] to [14] in the manufacture of a pharmaceutical composition.
- the crystal in the embodiment [27] is preferably the type I crystal described in any one of the embodiments [1] to [6].
- a twenty-eighth aspect of the present invention is the use of the crystal according to any one of the aforementioned aspects [1] to [14] as a TRPV1 antagonist.
- the crystal in the aspect [28] is preferably the type I crystal according to any one of the aspects [1] to [6].
- a twenty-ninth aspect of the present invention is the use of the crystal according to any one of the aspects [1] to [14] in the production of a TRPV1 antagonist.
- the crystal in the embodiment [29] is preferably the type I crystal described in any one of the embodiments [1] to [6].
- a thirtieth aspect of the present invention is a method for treating at least one disease selected from the group consisting of the diseases according to the nineteenth aspect of the present invention, which is effective for treating the disease. And administering a sufficient amount of the crystal according to any one of the embodiments [1] to [14] to a subject in need of treatment for the disease.
- the crystal in the aspect [30] is preferably the type I crystal according to any one of the aspects [1] to [6].
- a thirty-first aspect of the present invention is a method for treating at least one disease selected from the group consisting of the diseases according to the nineteenth aspect of the present invention, which is effective for antagonizing TRPV1.
- a method comprising administering an amount of a crystal according to any one of the aspects [1] to [14] to a subject in need of treatment for the disease.
- the crystal in the aspect [31] is preferably the type I crystal according to any one of the aspects [1] to [6].
- TRPV1 antagonistic action of the crystal according to any one of the aspects [1] to [14] of the present invention is measured by a method selected as appropriate, for example, Pharmacological Experimental Example 1 (human-derived TRPV1 antagonistic action) described later. Can do.
- the crystal according to any one of aspects [1] to [14] of the present invention has excellent TRPV1 antagonistic activity in Pharmacological Experimental Example 1 (human TRPV1 antagonistic action).
- a crystal analysis method by X-ray diffraction is generally used as a method for analyzing the obtained crystal.
- examples of the method for determining the crystal orientation include a mechanical method and an optical method (for example, FT-Raman spectrum, solid NMR spectrum) and the like.
- thermal analysis of crystals differential scanning calorimetry, differential scanning calorimetry (DSC)), infrared absorption spectrum (IR) analysis (KBr method, solution method) and the like can also be measured according to ordinary methods.
- Crystals of the present invention also include those having spectral peak values within the error range.
- Crystals of the present invention also include those having spectral peak values within the error range.
- the diffraction angle (2 ⁇ ) of powder X-ray diffraction samples with different specific crystal forms will share the same main peak of diffraction angle (2 ⁇ ), but with regard to secondary peaks, powder X-rays Differences in diffraction patterns can occur.
- the diffraction angle (2 ⁇ ) of powder X-ray diffraction it means that an error of “ ⁇ 0.2” or “ ⁇ 0.1” is allowed.
- the diffraction angle (2 ⁇ ) in powder X-ray diffraction may cause an error within a range of ⁇ 0.2 °.
- (about) diffraction angle (2 ⁇ ) X ° refers to “diffraction angle (2 ⁇ ) ((X ⁇ 0.2) to (X + 0.2)) ° unless otherwise specified.
- the present invention includes not only crystals whose diffraction angles in powder X-ray diffraction completely match but also crystals whose diffraction angles match within an error range of ⁇ 0.2 °.
- the “characteristic peak” means, for example, the diffraction angles (2 ⁇ ) having the values listed in Table 2, Table 3, Table 5, and Table 7. It means a peak showing maximum absorption.
- relative intensity (%) with respect to each diffraction angle (2 ⁇ ) of powder X-ray diffraction the X-ray intensity of each peak may vary depending on the size and direction of the crystal, and sometimes it may not be visible. Varies depending on measurement conditions.
- the type I crystal of the present invention is characterized in that a differential scanning calorimetry (DSC measurement) extrapolation melting point starting temperature is 232 ° C. under a temperature increase rate of 10 ° C./min.
- DSC measurement differential scanning calorimetry
- the melting point starting temperature is a temperature in the vicinity of the melting point of type I.
- the type III crystal of the present invention is characterized in that, when powder X-ray diffraction is performed under variable temperature conditions, a transition to a type I crystal is observed at around 170 ° C. while the temperature rises.
- Form I crystals include (E) -2- (7-trifluoromethylchroman-4-ylidene) -N-((7R) -7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) acetamide of the present invention
- Form I crystals include (E) -2- (7-trifluoromethylchroman-4-ylidene) -N-((7R) -7-hydroxy-5,6,7,8-tetrahydro including multiple crystal forms It can be prepared by transferring crystals of naphthalen-1-yl) acetamide (for example, type II crystals and / or type III crystals). For example, by heating the crystal at a temperature of 170 ° C. or higher, it is possible to transfer a II-type or III-type crystal to an I-type crystal.
- crystal transition is a phenomenon in which the crystal structure changes when a certain temperature or pressure is exceeded.
- crystal transition method include methods known per se, such as crystallization from a solution (eg, concentration method, slow cooling method, reaction method (diffusion method, electrolytic method), hydrothermal growth method, flux method, etc.
- Crystallization from vapor for example, vaporization method (sealed tube method, air flow method), gas phase reaction method, chemical transport method), crystallization from melt (for example, normal freezing method (pulling method, temperature gradient method) , Bridgman method), zone melting method (zone leveling method, float zone method), special growth method (VLS method, liquid phase epitaxy method)), transpiration method (dissolve crystals in solvent, evaporate the solvent under atmospheric conditions after filtration) Method), slurry method (a method in which crystals are added to a solvent so as to leave an excess solid to form a suspension, and the mixture is stirred at atmospheric temperature or under heating or cooling, and then the solid is collected by filtration), dried under reduced pressure, ground, Examples thereof include pulverization and pressurization.
- melt for example, normal freezing method (pulling method, temperature gradient method) , Bridgman method), zone melting method (zone leveling method, float zone method), special growth method (VLS method, liquid phase epitaxy method)
- transpiration method dissolv
- the alcohol solvent used in obtaining the type I crystal is preferably methanol, ethanol, or 2-propanol, and more preferably. Is methanol or ethanol, more preferably ethanol.
- the solvent used for obtaining the type I crystal is preferably a mixed solvent of an alcohol solvent and acetone. Examples thereof include alcohol solvents such as methanol or ethanol, or mixed solvents of alcohol solvents and acetone. Preferably, it is a mixed solvent with ethanol and acetone from the viewpoint of solubility and recovery.
- a part of the mixed solvent to be used may be mixed with the water to be used. For example, when the mixed solvent: water is 20:10, the mixed solvent 15 may be heated and dissolved using the mixed solvent 15, and the mixed solvent 5 and the water 10 may be appropriately mixed and used.
- the amount of the mixed solvent used is about 10 mL with respect to 1 g of the solid amount of the compound to be dissolved.
- Water in the method for producing type I crystal of the present invention (the above embodiment [15]) is preferably added gradually without being added at once.
- the dropping speed is not particularly limited.
- the cooling time to room temperature is not particularly limited as long as the temperature of the solvent sufficiently returns to room temperature.
- the solvent or mixed solvent used to obtain the type I crystal the mixing ratio of the solvent or mixed solvent and water, and the use of the mixed solvent
- the conditions consisting of the amount, the addition of water, and the cooling time to room temperature can be appropriately combined and set.
- the solvent used for obtaining the type II crystal is an ester solvent, an alcohol solvent, or a mixed solvent of an ester solvent and an alcohol solvent. Is mentioned.
- the ester solvent is preferably ethyl acetate
- the alcohol solvent is preferably methanol
- the amount of the mixed solvent of ethyl acetate and methanol is about 40 to 50 mL with respect to 1 g of the solid amount of the compound to be dissolved.
- a condition comprising the solvent or mixed solvent used for obtaining the type II crystal, the mixing ratio of the mixed solvent, and the amount of the mixed solvent used. Can be appropriately combined and set.
- dimethyl sulfoxide is preferable.
- the addition amount of dimethyl sulfoxide and water is 1 to 2 times, preferably 1.5 times the volume of dimethyl sulfoxide for dissolving the solid.
- the amount of dimethyl sulfoxide to be dissolved first is about 10 mL with respect to 1 g of the solid amount of the compound to be dissolved.
- the polar solvent used for obtaining the type III crystal the mixing ratio of the polar solvent and water, the addition amount of the polar solvent and water, In addition, the conditions composed of the amount of the polar solvent to be dissolved first can be appropriately combined and set.
- crystallization is performed at a temperature of about ⁇ 30 ° C. to 80 ° C., and the type I crystal is preferably heated from room temperature (1-30 ° C.) to a temperature of 60-70 ° C.
- the compound to be crystallized is dissolved at a temperature at which it completely dissolves, and the crystals of type II and III are performed at room temperature (1 ° C. to 30 ° C.).
- the type I crystal is crystallized under certain conditions to obtain a needle-like form (acicular crystal) as shown in FIG.
- the type II crystal is obtained in a columnar form (columnar crystal) as shown in FIG. 6 by crystallization under certain conditions.
- needle-like means a needle-like prism. This shape is also called “needle thread”.
- collettivo means an elongated prismatic crystal grown in parallel in one direction.
- the chemical purity of the type I crystal, type II crystal or type III is about 95% to 100%, preferably about 97% to 100%, and more preferably about 99% to 100%.
- type I crystals have good results in at least one test selected from the group consisting of a stability test such as a long-term storage test, an acceleration test, and a light stability test, and preferably a hygroscopic property. Therefore, it is a crystal useful as a pharmaceutical product.
- type I crystals are crystals that are excellent in thermodynamic stability, and therefore are easy to handle, prevent the transformation of crystal polymorphs in the pharmaceutical production process, The quality can be maintained, and a solid pharmaceutical composition (pharmaceutical preparation) can be produced with good reproducibility, which can be a useful crystal.
- type I crystals have very high chemical and physical stability, and can be used as a therapeutic and / or prophylactic agent for pain and the like having a TRPV1 antagonistic action.
- pain is a feature of many trauma and disease states. When substantial damage to body tissue occurs through disease or trauma, the characteristics of nociceptor activation change, leading to hypersensitivity at the site of injury and nearby normal tissue.
- Specific pain includes osteoarthritis pain, joint pain, neuropathic pain, postoperative pain, low back pain, and diabetic neuropathy, intraoperative pain, cancer pain, chemotherapy-induced pain, headache (cluster headache, tension) Headache, including migraine pain), trigeminal pain, herpes zoster pain, postherpetic neuralgia, carpal tunnel syndrome, inflammatory pain, pain from rheumatoid arthritis, colitis, interstitial cystitis pain, viscera Pain, pain from kidney stones, pain from gallstones, sore throat, fibromyalgia, chronic pain syndrome, thalamic pain syndrome, pain from stroke, phantom limb pain, sunburn, radiculopathy, complex local pain syndrome, HIV sensation Neuropathy, CNS pain syndrome, multiple sclerosis pain, Parkinson's
- each enantiomer of the title compound was separated into the first fraction (69 mg, white solid, 99.9% ee, retention time 9.9 minutes: Compound A-1), and the second fraction (71 mg, white solid, 99 3% ee, retention time 17.3 minutes: compound A-2).
- Compound A-1 which is the first fraction separated by the optical resolution column, is (E) -2- (7-trifluoromethylchroman-4-ylidene) -N-((7R) -7-hydroxy-5. , 6,7,8-tetrahydronaphthalen-1-yl) acetamide (compound (1)) and the second fraction, compound A-2, is (E) -2- (7-trifluoromethylchroman- 4-Ilidene) -N-((7S) -7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) acetamide.
- composition agent with crystal of the present invention or pharmaceutical composition thereof can be used in combination with other drugs or drugs by a general method performed in the medical field.
- analgesics include opioid agonists typified by morphine, or gabapentin, antidepressants such as pregabalin, duloxetine, or amitriptyline; antidepressants such as carbamazepine and phenytoin; and antiarrhythmic drugs such as mexiletine.
- Anti-inflammatory drugs such as those that have been diverted to neuropathic pain and prescribed, NSAIDs typified by diclofenac, indomethacin, ibuprofen, naproxen, and COX-2 inhibitors typified by Celebrex.
- NSAIDs typified by diclofenac, indomethacin, ibuprofen, naproxen, and COX-2 inhibitors typified by Celebrex.
- the crystal of the present invention or a pharmaceutical composition thereof can be used not only in combination with other drugs but also in combination with other therapeutic methods. Specific examples include acupuncture, laser treatment, and nerve block. In diseases involving TRPV1 other than pain, the crystal of the present invention or a pharmaceutical composition thereof can be used in combination with a drug used in each region. For example, it can be used in combination with NSAIDs, DMARDs, anti-TNF ⁇ antibodies, soluble TNF ⁇ receptors, steroids, immunosuppressants and the like that are commonly used in chronic rheumatoid arthritis. In addition, in COPD and allergic diseases, it can be used in combination with general therapeutic agents such as ⁇ 2 receptor agonists and steroids. Furthermore, for overactive bladder and urinary incontinence, it can be combined with anticholinergic drugs.
- the dosage of existing drugs can be reduced, and the side effects of existing drugs can be reduced.
- the combination method using the said drug is not limited to the said disease, and the drug used together is not limited to the compound illustrated above.
- the drug used in combination with the crystal of the present invention may be a separate preparation or a combination. Moreover, in separate preparations, both can be taken simultaneously or can be administered at different times.
- the crystalline pharmaceutical composition of the present invention comprises (E) -2- (7-trifluoromethylchroman-4-ylidene) -N-((7R) -7-hydroxy-5,6,7,8 of the present invention. -Containing tetrahydronaphthalen-1-yl) acetamide crystals and made in combination with pharmaceutically acceptable additives.
- excipients eg; lactose, sucrose, mannitol, crystalline cellulose, silicic acid, corn starch, potato starch
- binders eg; celluloses (hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC) )
- Crystalline cellulose sugar (lactose, mannitol, sucrose, sorbitol, erythritol, xylitol,), starches (corn starch, potato starch), pregelatinized starch, dextrin, polyvinylpyrrolidone (PVP), macrogol, polyvinyl alcohol ( PVA)), lubricants (eg; magnesium stearate, calcium stearate, talc, carboxymethylcellulose), disintegrants (eg; starches (corn starch, potato starch), sodium carboxymethyl starch , Carmellose, carmellose calcium, croscarmellose sodium, crospovidone), coating agents (eg, cellulose
- Various dosage forms include tablets, capsules, granules, powders, pills, aerosols, inhalants, ointments, patches, suppositories, injections, lozenges, liquids, spirits, suspensions, Examples include extract and elixir.
- Oral subcutaneous administration, intramuscular administration, intranasal administration, transdermal administration, intravenous administration, intraarterial administration, perineural administration, epidural administration, intradural administration, intraventricular administration, intrarectal administration It can be administered to a patient by inhalation or the like. *
- the dose of the crystal of the present invention is usually 0.005 mg to 3.0 g, preferably 0.05 mg to 2.5 g, more preferably 0.1 mg to 1.5 g per day for an adult. It can be increased or decreased accordingly.
- the entire amount can be divided into 1 or 2-6 doses, orally or parenterally, or can be administered continuously by intravenous infusion.
- Pharmacological Example 1 provides a method for testing the effectiveness of the crystals of the present invention.
- Pharmacological Experiment Example 1 Measurement of capsaicin-induced Ca influx in human TRPV1-transformed CHO cell line
- (1) Establishment of human TRPV1-transformed CHO cell line
- Human vanilloid receptor 1 (hTRPV1) cDNA was cloned from human brain.
- the cloned hTRPV1 cDNA was incorporated into the pCAGGS vector, which was introduced into the CHO-K1 cell line and transformed.
- Clones obtained by limiting dilution were stimulated with capsaicin, and clones with high response were selected using an increase in Ca concentration as an index. Selected clones were used for experiments.
- TRPV1 antagonistic activity of acetamide is shown in Table 1 as A2 value.
- the crystal of the present invention has an excellent TRPV1 antagonistic action.
- the crystal of the present invention is an excellent TRPV1 antagonist, as acute pain, chronic pain, neuropathic pain, postherpetic neuralgia, trigeminal neuralgia, low back pain, pain after spinal cord injury, lower limb pain, causalgia, diabetic neuralgia, edema , Burns, sprains, pain due to fracture, post-operative pain, peri-arthritis, osteoarthritis, arthritis, rheumatoid arthritis pain, inflammatory pain, cancer pain, migraine, headache, toothache, neuralgia, muscle pain, Hyperalgesia, pain due to angina and menstruation, neuropathy, nerve damage, neurodegeneration, chronic obstructive pulmonary disease (COPD), asthma, airway hypersensitivity, wheezing, cough, rhinitis, inflammation of the mucous membrane of the eyes, neurological skin disease , Psoriasis, eczema inflammatory skin disease, edema, allergic disease, gastroduodenal ulcer,
- Root temperature in the examples usually indicates a temperature of 1 ° C. to 30 ° C. (Japanese Pharmacopoeia regulations).
- Powder X-ray diffraction analysis was performed using D8 Discover with GADDS CS (Bruker), Bragg-Brentano method (X-ray source: 40 kV, 40 mA, Wavelength: 1.5418 ⁇ ⁇ (Angstrom), CuK: 250 mm, temperature: room temperature, Phi Position: 0 degree, Exposure time: 2 minutes, Theta 1: 7 degrees, Theta 2: 7 degrees).
- DSC Differential scanning calorimetry
- the measurement result of powder X-ray diffraction of the I-type crystal is shown in FIG. 1, the peak of the I-type crystal is shown in Table 2, and the more characteristic peak is shown in Table 3. Moreover, the microscope picture of this type I crystal is shown in FIG. The FT-IR spectrum data of the type I crystal is shown in FIG. The DSC thermal analysis data of the type I crystal is shown in FIG. In the DSC thermal analysis data, there is no significant endothermic / exothermic peak depending on the temperature from room temperature to the melting point.
- Example 2 Compound (1) (200 mg) was dissolved in acetone / ethanol (99.5%) (7/3) (15 mL) by heating at 60 ° C., and water (14 mL) was added with heating (20 minutes). Then, it stood to cool to room temperature. The precipitated crystals were filtered, and washed successively with ethanol / water (1/1) and water. The obtained crystals were dried under reduced pressure to obtain white crystals (188 mg) as type I crystals. When the powder X-ray diffraction was measured, the characteristic peaks of the type I crystals shown in Table 3 were observed.
- FIG. 5 shows the measurement result of powder X-ray diffraction of the type II crystal
- Table 5 shows the characteristic peaks of the type II crystal.
- a micrograph of the crystal is shown in FIG.
- FT-IR spectrum data of the crystals are shown in FIG.
- DSC thermal analysis data of the crystal is shown in FIG. During the DSC thermal analysis, a slight endotherm was observed at around 170 to 200 ° C., and it was confirmed that the crystal form changed under the microscope.
- Example 4 (E) -2- (7-trifluoromethylchroman-4-ylidene) -N-((7R) -7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) acetamide type III crystal Compound (1) (1.5 g) was dissolved in dimethyl sulfoxide (15 mL). Dimethyl sulfoxide / water (1/2) (22.5 mL) was added in three portions, added at room temperature with stirring, and stirred for 30 minutes. The produced crystals were filtered, and the obtained crystals were washed with ethanol / water (1/4) (3 mL, 2 times), water (3 mL, 2 times), and ethanol (3 mL). The crystals were dried under reduced pressure at 40 ° C. for 2 hours to obtain white crystals (1.41 g) as type III crystals.
- the measurement result of powder X-ray diffraction of the type III crystal is shown in FIG. 9, and the characteristic peaks of the type III crystal are shown in Table 7.
- the type I crystal of the present invention is thermodynamically stable in a suspended state at 25 ° C. Therefore, by using the type I crystal of the present invention for a pharmaceutical product, it is possible to prevent metastasis in the pharmaceutical production process and maintain the quality of the drug substance or the pharmaceutical product.
- the type II crystal of the present invention is unstable to light, and the type I crystal has very high chemical and physical stability. Accordingly, type I crystals are easy to handle as a drug substance during the manufacture of pharmaceuticals and are suitable for drug substances and pharmaceutical preparations.
- there is no photodegradation or isomerization of the structure of the compound and there is no decrease in biological activity, so there is no impact on bioavailability and it is possible to maintain the stability of pharmaceutical properties as a pharmaceutical product. Also, the shelf life can be long.
- the compound (1) of the present invention has a chroman-4-ylidene structure, and it may be concerned that the structure is rearranged to 2H-chromene structure by light irradiation. There may also be concern about a decrease in biological activity due to the event.
- Formulation Example 1 Type I crystal of tablet Example 1 100 g 137g of lactose Crystalline cellulose 30g Hydroxypropylcellulose 15g Carboxymethyl starch sodium 15g Magnesium stearate 3g Weigh the above ingredients and mix evenly. This mixture is compressed into tablets having a weight of 150 mg.
- Formulation Example 2 Capsule Example 1 Form I Crystal 50g Lactose 435g Magnesium stearate 15g The above ingredients are weighed and mixed uniformly. The mixture is filled into an appropriate hard capsule in an amount of 300 mg in a capsule encapsulator to obtain a capsule.
- Example 3 Capsule Example 1 Type I Crystal 100 g Lactose 63g Corn starch 25g Hydroxypropylcellulose 10g Talc 2g After weighing the above components, type I crystals of Example 1, lactose and corn starch are uniformly mixed, an aqueous solution of hydroxypropylcellulose is added, and granules are produced by wet granulation. Talc is uniformly mixed into the granules, and 200 mg in weight is filled into an appropriate hard capsule to form a pushell.
- the crystal of the present invention exhibits an excellent TRPV1 antagonistic action, it can provide a clinically useful prophylactic and / or therapeutic agent for diseases such as pain.
- the crystal of the present invention is excellent in at least one characteristic selected from the group consisting of storage stability, light stability, and thermodynamic stability, and preferably has high yield and high purity with good industrial reproducibility. And is useful as a crystal of an active pharmaceutical ingredient.
- the method for producing a crystal of the present invention is such that the crystal can be supplied easily, in good yield, with good reproducibility, industrially, and from the viewpoint of stable supply to product production. Useful.
- providing a crystal of the compound (1) as described above is useful because it makes it possible to provide a pharmaceutical composition having excellent stability.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
Description
より具体的には、例えば、熱力学的安定性を有することで言えば、医薬品製造過程での結晶多形の転移を未然に防ぎ、原薬や医薬品の品質を保持することになる。また、例えば、保存安定性を有することで言えば、化学的・物理学的に安定であり、吸湿性が無いことにより、原薬として長期間に渡ってその品質が規格内に保持され、医薬品への加工がしやすく、医薬品製剤に使用が可能となる。さらに、例えば、光安定性を有することで言えば、医薬品原薬となる結晶を光照射下に曝した際、光分解が無いことにより、原薬が有する生物活性が低下することが無いことから、生物学的利用能への影響がなく、医薬品としての製剤特性の安定性の保持が可能となり、又、保管寿命が長期にもなり得る。
医薬に用いる化合物の結晶は、従来取得できていた同じ方法を用いても、種々の結晶化条件により、同じ結晶形の取得が困難になる場合もあることから、簡便な方法で、収率が良く、再現性が良く、安定的に供給できる工業的に応用可能な結晶の製造方法が求められる。
また、上記のような化合物(1)の結晶を提供することで、安定性に優れた医薬組成物の提供が可能となる。
本発明の化合物(1)のI型結晶を有効成分として含有する医薬組成物は、TRPV1が関与している疾患の予防剤及び/又は治療剤として期待される。
本発明の化合物(1)のI型結晶は、好ましくは、熱力学的に安定性であり、医薬品製造過程での結晶多形の転移を未然に防ぎ、原薬や医薬品の品質を保持することが可能である。
また、保存安定性を有することで言えば、好ましくは、化学的・物理学的に安定であり、吸湿性が無いことにより、原薬として長期間に渡ってその品質が規格内に保持され、医薬品への加工がしやすく、医薬品製剤に使用が可能である。
さらに、優れた光安定性を有することで言えば、好ましくは、光分解や化合物の構造の異性化が起こらずに、生物活性の低下が生じないことから、生物学的利用能への影響がなく、医薬品としての製剤特性の安定性の保持が可能となり、又、保管寿命が長期にもなり得る。
本発明の化合物(1)のI型結晶の製造方法は、好ましくは、簡便な方法であり、収率が良く、純度が高く、再現性良く、I型結晶を供給できることから、工業的に利用可能である。
本発明の化合物(1)のI型結晶は、保存安定性、光安定性、熱力学的安定性等のからなる群より選択される少なくとも1つの特性に優れることから、安定性等に優れた医薬組成物を提供することが可能である。
更に、本発明は、化合物(1)のII型結晶又はIII型結晶の製造方法にも関する。
ここで、本明細書において、態様[1]~態様[14]のいずれかに記載の結晶を、「本発明の(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドの結晶」、「化合物(1)の結晶」又は「本発明の結晶」という場合がある。
態様[1]~態様[6]のいずれかに記載の結晶を、「本発明のI型結晶」という場合がある。
態様[7]~態様[11]のいずれかに記載の結晶を「本発明のII型結晶」という場合がある。
態様[12]~態様[14]のいずれかに記載の結晶を「本発明のIII型結晶」という場合がある。
なくとも、約7.9、約10.3、約15.8、約16.4、約17.2、約19.5、約19.9、約21.6、約23.9、約25.0及び約26.7(°)に特徴的ピークを有する、(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドのI型結晶である。
[1-1]本発明の第1-1の態様は、粉末X線回折による回折角(2θ)として、約7.9、約8.9、約10.3、約12.0 、約15.8 、約16.4、約17.2、約17.6、約18.3、約19.5、約19.9、約20.8、約21.6、約23.9、約24.6、約25.0、約26.3、約26.7、約27.7、約28.6、約29.5、約31.4、約32.4、約33.2、約33.8及び約34.8(°)に特徴的ピークを有する、(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドのI型結晶である。
[15-2]前記態様[15]又は態様[15-1]におけるアルコール系溶媒は、好ましくは、メタノール、エタノール、又は2-プロパノールであり、より好ましくは、メタノール又はエタノールあり、更に好ましくは、エタノールである。
[15-3]前記態様[15]ないし[15-2]のいずれか1態様に記載の製造方法におけるアルコール系溶媒とアセトンとの混合溶媒の混合比は、1:9~9:1(体積:体積、v/v)の範囲で適宜選択できる。より具体的には、エタノール:アセトン=1:1又は3:7等が挙げられる。当該混合溶媒と使用する水の量の比率は、混合溶媒:水=3:1~2:1である。使用する混合溶媒の一部は使用する水と混合して使用してもよい。例えば、混合溶媒:水が20:10であれば、混合溶媒15を使用して加熱溶解し、混合溶媒5と水10を適宜混ぜて使用してもよい。混合溶媒の使用量は、溶解させる化合物の固体量1gに対して10mL程度である。
[15-4]前記態様[15]ないし態様[15-3]のいずれか1態様に記載の製造方法における水は、一度に加えないで、徐々に加えることが好ましい。滴下速度は特に制限はない。
[15-5]前記態様[15]において、室温までの放冷時間は、溶媒の温度が十分室温に戻る時間であれば、特に制限はない。
[18-1]前記態様[18]における結晶は、好ましくは前記態様[1]ないし態様[6]のいずれか1態様に記載のI型結晶である。
[19-1]前記態様[19]における結晶は、好ましくは前記態様[1]ないし態様[6]のいずれか1態様に記載のI型結晶である。
本明細書中、「予防する」は、患者の状態に応じて、「疾患」の発症又はその「疾患」に関連する任意の症状の発症を予防することを意味する。「疾患」の予防、ならびに発症前に「疾患」又はその任意の症状の重症度を低減することも包含する
[20-1]前記態様[20]における結晶は、好ましくは前記態様[1]ないし態様[6]のいずれか1態様に記載のI型結晶である。
[21-2]前記態様[21]及び[21-1]における結晶は、好ましくは前記態様[1]ないし態様[6]のいずれか1態様に記載のI型結晶である。
[22-2]前記態様[22]及び[22-1]における結晶は、好ましくは前記態様[1]ないし態様[6]のいずれか1態様に記載のI型結晶である。
[23-1]前記態様[23]における結晶は、好ましくは前記態様[1]ないし態様[6]のいずれか1態様に記載のI型結晶である。
[24-1]前記態様[24]における結晶は、好ましくは前記態様[1]ないし態様[6]のいずれか1態様に記載のI型結晶である。
[25-1]前記態様[25]における結晶は、好ましくは前記態様[1]ないし態様[6]のいずれか1態様に記載のI型結晶である。
[26-1]前記態様[26]における結晶は、好ましくは前記態様[1]ないし態様[6]のいずれか1態様に記載のI型結晶である。
[27-1]前記態様[27]における結晶は、好ましくは前記態様[1]ないし態様[6]のいずれか1態様に記載のI型結晶である。
[28-1]前記態様[28]における結晶は、好ましくは前記態様[1]ないし態様[6]のいずれか1態様に記載のI型結晶である。
[29-1]前記態様[29]における結晶は、好ましくは前記態様[1]ないし態様[6]のいずれか1態様に記載のI型結晶である。
[30-1]前記態様[30]における結晶は、好ましくは前記態様[1]ないし態様[6]のいずれか1態様に記載のI型結晶である。
[31-1]前記態様[31]における結晶は、好ましくは前記態様[1]ないし態様[6]のいずれか1態様に記載のI型結晶である。
本発明における(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドの結晶は、いずれの結晶形も水和物ではなく、すなわち無水物である。
例えば、粉末X線回折の回折角(2θ)においては、特定の結晶形の異なる試料は、回析角(2θ)の同じ主要ピークを共有することになるが、副次ピークに関しては粉末X線回折パターンに差が生じ得る。粉末X線回折の回折角(2θ)においては、「±0.2」又は「±0.1」の誤差が、許容されることを意味する。一般に、粉末X線回折における回折角度(2θ)は、±0.2°の範囲内で誤差が生じ得る。したがって、本発明で「(約)回折角度(2θ)X°」というときは、特に記載した場合を除き、「回折角度(2θ)((X-0.2)~(X+0.2))°」を意味する。粉末X線回折における回折角度が完全に一致する結晶だけでなく、回折角度が±0.2°の誤差範囲内で一致する結晶も本発明に含まれる。
「結晶転移法」としては、自体公知の方法が挙げられ、例えば、溶液からの結晶化(例えば、濃縮法、徐冷法、反応法(拡散法、電解法)、水熱育成法、融剤法など)、蒸気からの結晶化(例えば、気化法(封管法、気流法)、気相反応法、化学輸送法)、溶融体からの結晶化(例えば、ノルマルフリージング法(引き上げ法、温度傾斜法、ブリッジマン法)、帯溶融法(ゾーンレベリング法、フロートゾーン法)、特殊成長法(VLS法、液相エピタキシー法))、蒸散法(結晶を溶媒に溶かし、ろ過後大気条件で溶媒を蒸発させる方法)、スラリー法(過剰の固体が残るように溶媒に結晶を添加して懸濁液とし、大気温度又は加熱あるいは冷却下で攪拌後、固体を濾集する方法)、減圧乾燥、すり潰し、粉砕、加圧などが挙げられる。
本発明のI型結晶の製造方法(前記態様[15])において、I型結晶を取得する為に用いる溶媒としては、好ましくは、アルコール系溶媒とアセトンとの混合溶媒である。メタノール又はエタノール等のアルコール系溶媒、又はアルコール系溶媒とアセトンとの混合溶媒が挙げられる。好ましくは、溶解性や回収率の点からエタノール及びアセトンとの混合溶媒である。
本発明のI型結晶の製造方法(前記態様[15])において、室温までの放冷時間は、溶媒の温度が十分室温に戻る時間であれば、特に制限はない。
化合物(1)は、国際公開第2007/010383号パンフレットの実施例70で得られた灰色固体の化合物((E)-2-(7-トリフルオロメチル-クロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド(化合物A))を、国際公開第2007/010383号パンフレットの(実施例71、実施例72)に記載の方法に準じて、光学分割することで製造することができる。当該光学分割は、例えば、光学分割カラムを用いた当業者に通常の方法により適宜分離可能であり、分離条件も適宜設定可能である。
本発明の結晶、又はその医薬組成物は、医療現場で行われている一般的な方法で、他の薬物もしくは薬剤と併用することも可能である。例えば、鎮痛薬としては、モルヒネを代表とするオピオイド作動薬、又はガバペンチンの他、プレガバリン、デュロキセチン、或いはアミトリプチリンなどの抗うつ薬;カルバマゼピン、フェニトインなどの抗癲癇薬;メキシレチンなどの抗不整脈薬等の神経因性疼痛に転用し、処方されているものやジクロフェナク、インドメタシン、イブプロフェン、ナプロキセンを代表とするNSAIDs、セレブレックスを代表とするCOX-2阻害薬などの抗炎症薬が挙げられる。好ましくは、モルヒネ、ガバペンチン又はプレガバリン、ジクロフェナク、セレブレックスである。
疼痛以外のTRPV1が関与する疾患では、本発明の結晶、又はその医薬組成物は、それぞれの領域で使用されている薬物との併用が可能である。例えば慢性リウマチ性関節炎などでは一般的に使用されているNSAIDs、DMARDsや抗TNFα抗体、可溶性TNFα受容体、ステロイド、免疫抑制剤などとの併用が可能である。また、COPDやアレルギー疾患ではβ2受容体作用薬やステロイドなどの一般的な治療薬との併用が可能である。また更に過活動性膀胱や尿失禁では、抗コリン薬との併用が可能である。
本発明の結晶の医薬組成物は、本発明の(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドの結晶を含み、医薬上許容される添加剤と組み合わせて作られる。
より詳細には、賦形剤(例;乳糖、白糖、マンニトール、結晶セルロース、ケイ酸、トウモロコシデンプン、バレイショデンプン)、結合剤(例;セルロース類(ヒドロキシプロピルセルロース(HPC)、ヒドロキシプロピルメチルセルロース(HPMC))、結晶セルロース、糖類(乳糖、マンニトール、白糖、ソルビトール、エリスリトール、キシリトール、)、デンプン類(トウモロコシデンプン、バレイショデンプン)、α化デンプン、デキストリン、ポリビニルピロリドン(PVP)、マクロゴール、ポリビニルアルコール(PVA))、滑沢剤(例;ステアリン酸マグネシウム、ステアリン酸カルシウム、タルク、カルボキシメチルセルロース)、崩壊剤(例;デンプン類(トウモロコシデンプン、バレイショデンプン)、カルボキシメチルスターチナトリウム、カルメロース、カルメロースカルシウム、クロスカルメロースナトリウム、クロスポピドン)、被膜剤(例;セルロース類(ヒドロキシプロピルセルロース(HPC)、ヒドロキシプロピルメチルセルロース(HPMC)、アミノアルキルメタクリレートコポリマーE、メタクリル酸コポリマーLD)、可塑剤(例;クエン酸トリエチル、マクロゴール)、隠蔽剤(例;酸化チタン)、着色剤、香味剤、防腐剤(例;塩化ベンザルコニウム、パラオキシ安息香酸エステル)、等張化剤(例;グリセリン、塩化ナトリウム、塩化カルシウム、マンニトール、ブドウ糖)、pH調節剤(例;水酸化ナトリウム、水酸化カリウム、炭酸ナトリウム、塩酸、硫酸、リン酸緩衝液などの緩衝液)、安定化剤(例;糖、糖アルコール、キサンタンガム)、分散剤、酸化防止剤(例;アスコルビン酸、ブチルヒドロキシアニソール(BHA)、没食子酸プロピル、dl-α-トコフェロール)、緩衝剤、保存剤(例;パラベン、ベンジルアルコール、塩化ベンザルコニウム)、芳香剤(例;バニリン、l-メントール、ローズ油)、溶解補助剤(例;ポリオキシエチレン硬化ヒマシ油、ポリソルベート80、ポリエチレングリコール、リン脂質コレステロール、トリエタノールアミン)、吸収促進剤(例;グリコール酸ナトリウム、エデト酸ナトリウム、カプリン酸ナトリウム、アシルカルニチン類、リモネン)、ゲル化剤、懸濁化剤、又は乳化剤、一般的に用いられる適当な添加剤又は溶媒の類を、本発明の結晶と適宜組み合わせて種々の剤形とすることが出来る。
全量を1回あるいは2-6回に分割して経口または非経口投与することや、点滴静注等、連続投与することも可能である。
以下に実験例を挙げて、本発明を具体的に説明するが、本発明はこれらによって何ら限定されるものではない。
以下の薬理実施例1は、本発明の結晶の有効性を試験する方法を提供する。
[薬理実験例1:ヒトTRPV1形質転換CHO細胞株におけるカプサイシン誘発性Ca流入の測定]
(1)ヒトTRPV1形質転換CHO細胞株の樹立
ヒトバニロイド受容体1(hTRPV1)cDNAをヒト脳からクローニングした。クローニングしたhTRPV1 cDNAをpCAGGSベクターに組み入れ、これをCHO-K1細胞株に遺伝子導入して、形質転換を行った。限界希釈により得られたクローンをカプサイシンで刺激し、Ca濃度増加を指標として高応答のクローンを選択した。選択されたクローンを実験に使用した。
ヒトTRPV1形質転換CHO細胞を96ウェルプレート(黒壁、透明底 / Greiner社製)に1ウェルあたり4万細胞の密度で播種した。1晩、37℃、5%CO2条件下で培養した後、2.5 mmol/L プロベネシドを添加したFLIPR Calcium 3 assay kit (Molecular Devices社製)のloading solutionを各ウェルに培地と同量添加し、細胞を37℃で60分間、培養した。カプサイシン (1 nmol/L - 1μmol/L) 刺激後3分間、FDSS-6000 (λex:480 nm,λem:540 nm,浜松ホトニクス)を用いて細胞内Ca濃度の変化を測定した。本発明の結晶処置群及び媒体群のそれぞれで細胞内Ca濃度増加率の積分値を算出し、カプサイシンの濃度反応曲線を作成した。媒体群処置時のカプサイシンの濃度反応曲線を右方に2倍移動させる本発明の結晶の濃度(A2値)を算出し、この値を指標として試験化合物の阻害効果を確認した。
国際公開第2007/010383号パンフレットに記載に実施例70の(E)-2-(7-トリフルオロメチル-クロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド(化合物A)を、分取クロマトグラフィー(カラム:(株)ダイセル化学工業製 CHIRALPAK AD-H、10cmID×25cm、溶媒 メタノール:アセトニトリル=9:1、流速 189mL/分、カラム温度40℃、サンプル濃度7g/L(EtOH))を用いて光学分割を行うことで化合物(1)を得る。
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドのI型結晶
化合物(1)(165.2g)をアセトン/エタノール(99.5%)(1/1)(1.6L)に60~70℃の温度で加熱溶解した。水(600mL)を攪拌下で加えた後、攪拌下で室温まで放冷した。析出した結晶をろ過し、エタノール/水(1/1)、水で順次結晶を洗浄した。得られた結晶を減圧下にて乾燥して、白色結晶(146.7g)をI型結晶として得た。
化合物(1)(200mg)をアセトン/エタノール(99.5%)(7/3)(15mL)に60℃で加熱溶解し、加熱しながら水(14mL)を加えた(20分)。その後、室温まで放冷した。析出した結晶をろ過し、エタノール/水(1/1)、水で順次結晶を洗浄した。得られた結晶を減圧下にて乾燥して、白色結晶(188mg)をI型結晶として得た。
粉末X線回折の測定をしたところ、表3に示したI型結晶に特徴的なピークを観察した。
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドのII型結晶
化合物(1)(40.0g)を酢酸エチル/メタノール(1440mL/400mL)に溶解し、減圧濃縮した。酢酸エチルを加え、懸濁溶液をろ過した後、減圧下にて乾燥して、白色結晶(33.6g)をII型結晶として得た。
DSC熱分析中、170~200℃付近で若干の吸熱が確認でき、顕微鏡下では結晶形が変化する様子が確認された。
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドのIII型結晶
化合物(1)(1.5g)をジメチルスルホキシド(15mL)に溶解した。ジメチルスルホキシド/水(1/2)(22.5mL)を3回に分けて、攪拌下室温で加え、30分間攪拌した。生成した結晶をろ過し、得られた結晶をエタノール/水(1/4)(3mL、2回)、水(3mL、2回)、エタノール(3mL)で洗浄した。結晶を40℃で2時間減圧乾燥して、白色結晶(1.41g)をIII型結晶として得た。
結晶化で得た(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドの各結晶形(I型結晶、II型結晶)を同重量ずつ混合した結晶形混合物を調製し、結晶形混合物を各種溶媒(アセトニトリル、エタノール、又は2-プロパノール)と混合し、25℃で5日間懸濁し(スラリーを形成し)、撹拌した。結晶をろ取し、粉末X線回折パターンを確認したところ、全てI型結晶であった。
この結果から、本発明のI型結晶は、25℃の条件下における懸濁状態で、熱力学的に安定であることが明らかとなった。従って、本発明のI型結晶を医薬品に用いることで、医薬品製造過程での転移を未然に防ぎ、原薬や医薬品の品質を保持することが可能である。
結晶化で得られた、(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドのI型及びII型結晶(約30mg)をガラス瓶に入れ、各条件下で保存した。保存期間完了後、試料を取り出し、高速液体クロマトグラフィーにて化学純度の測定及び粉末X線にて結晶形の確認を行った。結果を表8に示す。
結晶化で得られた、(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドのI型結晶(400mg)を2重のLDPE(低密度ポリエチレン)の袋に入れたのちファイバードラムに入れ、表9に記載の各条件下で保存した。保存期間完了後、試料を取り出し、高速液体クロマトグラフィーにて化学純度の測定及び粉末X線にて結晶形の確認を行った。結果を表9に示す。
従って、原薬として長期間にわたってその品質が規格内に保持され、当該期間にわたって、医薬品への加工がしやすく、医薬品製剤に使用可能である。
結晶化で得られた、(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドのI型結晶及びII型結晶(各々約2g)をガラス製の皿状容器に入れ、ICH Q1B(新原薬及び新製剤の光安定性試験ガイドライン)に準じる光安定性試験に付した(光安定性試験のサンプルは、可視光及びUV-A光を放つ別個のランプの下に保存し、約25℃にて、総暴露が各々120万ルクス時間及び200ワット時間/m2以上となるようにする。10日間の試験を1ICHと表記する)。試験終了後、試料を取り出し、高速液体クロマトグラフィーにて化学純度の測定及び粉末X線にて結晶形の確認を行った。結果を表10に示す。
本発明の化合物(1)は、クロマン-4-イリデン構造を有しており、光照射による当該構造が2H-クロメン構造へ転位されることが懸念し得る。又当該事象による生物活性低下も懸念し得る。
以下に、本発明の医薬組成物の例を挙げる。
製剤例1 錠剤
実施例1のI型結晶 100g
乳糖 137g
結晶セルロース 30g
ヒドロキシプロピルセルロース 15g
カルボキシメチルスターチナトリウム 15g
ステアリン酸マグネシウム 3g
上記成分を秤量した後,均一に混合する。この混合物を打錠して重量150mgの錠剤とする。
実施例1のI型結晶 50g
乳糖 435g
ステアリン酸マグネシウム 15g
上記成分を秤量した後、均一に混合する。混合物をカプセル封入器にて適当なハードカプセルに重量300mgずつ充填し、カプセル剤とする。
実施例1のI型結晶 100g
乳糖 63g
トウモロコシデンプン 25g
ヒドロキシプロピルセルロース 10g
タルク 2g
上記成分を秤量した後、実施例1のI型結晶、乳糖、トウモロコシデンプンを均一に混合し、ヒドロキシプロピルセルロースの水溶液を加え、湿式造粒法により顆粒を製造する。この顆粒にタルクを均一に混合し,適当なハードカプセルに重量200mgずつ充填し,プセル剤とする。
実施例1のI型結晶 200g
乳糖 790g
ステアリン酸マグネシウム 10g
上記成分をそれぞれ秤量した後、均一に混合し、20%散剤とする。
また、本発明の結晶は、保存安定性、光安定性、熱力学的安定性からなる群より選択される少なくとも1つの特性に優れ、好ましくは、工業的に再現性良く高収率及び高純度で得られ、医薬品原薬の結晶として有用である。また、好ましくは、本発明の結晶の製造方法は、当該結晶を簡便に、収率が良く、再現性良く、工業的に供給可能であり、また製品製造への安定的な供給の点からも有用である。また、上記のような化合物(1)の結晶を提供することで、安定性に優れた医薬組成物の提供が可能となり有用である。
Claims (10)
- 粉末X線回折(Cu-Ka)による回折角(2θ)として、少なくとも、約7.9 、約10.3、約15.8、約16.4、約17.2、約19.5、約19.9、約21.6、約23.9、約25.0及び約26.7(°)に特徴的ピークを有する、(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドのI型結晶。
- 粉末X線回折(Cu-Ka)による回折角(2θ)として、約7.9、約8.9、約10.3、約12.0 、約15.8 、約16.4、約17.2、約17.6、約18.3、約19.5、約19.9、約20.8、約21.6、約23.9、約24.6、約25.0、約26.3、約26.7、約27.7、約28.6、約29.5、約31.4、約32.4、約33.2、約33.8及び約34.8(°)に特徴的ピークを有する、(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドのI型結晶。
- 図1に示す粉末X線回折図により特徴付けられる、(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドのI型結晶。
- 示差走査熱量測定(DSC測定)外挿融点開始温度が、232℃であることを特徴とする、請求項1ないし請求項3のいずれかに1項に記載のI型結晶。
- 針状結晶の形態の請求項1ないし請求項4のいずれか1項に記載のI型結晶。
- (E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドをアルコール系溶媒、又はアルコール系溶媒及びアセトンとの混合溶媒から選ばれる溶媒を用いて加熱下溶解させた後、加熱撹拌下に水を加えた後、当該水を含む混合溶液を撹拌下で室温まで放冷することで結晶を得る段階を含む、請求項1ないし請求項5のいずれか1項に記載の((E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドのI型結晶の製造方法。
- 請求項1ないし請求項5のいずれか1項に記載の結晶を有効成分として含有する医薬組成物。
- TRPV1拮抗剤である、請求項7記載の医薬組成物。
- 急性疼痛、慢性疼痛、神経因性疼痛、ヘルペス後神経痛、三叉神経痛、腰痛、脊髄損傷後疼痛、下肢痛、カウザルギー、糖尿病性神経痛、浮腫、火傷、捻挫、骨折による痛み、手術後疼痛、肩関節周囲炎、変形性関節症、関節炎、リウマチ性関節炎痛、炎症性疼痛、癌性疼痛、偏頭痛、頭痛、歯痛、神経痛、筋肉痛、痛覚過敏、狭心症や月経による疼痛、神経障害、神経損傷、神経変性、慢性閉塞性肺疾患(COPD)、喘息、気道過敏、喘鳴、咳、鼻炎、目の粘膜の炎症、神経性皮膚疾患、乾癬、湿疹の炎症性皮膚疾患、浮腫、アレルギー疾患、胃十二指腸潰瘍、潰瘍性大腸炎、過敏性大腸、クローン病、尿失禁、切迫性尿失禁、過活動性膀胱、膀胱炎、腎炎、膵炎、ブドウ膜炎、内臓障害、虚血、卒中、失調症、肥満、敗血症、及びそう痒症からなる群から選択される少なくとも1つの疾患の予防剤及び/又は治療剤である請求項7記載の医薬組成物。
- 医薬組成物の製造における、請求項1ないし請求項5のいずれか1項に記載の結晶の使用。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18810263.6A EP3636640B1 (en) | 2017-05-31 | 2018-05-30 | Crystal of heterocyclidene acetamide derivative |
MX2019014216A MX2019014216A (es) | 2017-05-31 | 2018-05-30 | Cristal de derivado de heterociclideno acetamida. |
CA3059483A CA3059483A1 (en) | 2017-05-31 | 2018-05-30 | Crystal of heterocyclidene acetamide derivative |
CN201880035532.5A CN110831930B (zh) | 2017-05-31 | 2018-05-30 | 杂环亚基乙酰胺衍生物的晶体 |
PL18810263.6T PL3636640T3 (pl) | 2017-05-31 | 2018-05-30 | Kryształ heterocyklidenowej pochodnej acetamidu |
RU2019137598A RU2779198C2 (ru) | 2017-05-31 | 2018-05-30 | Кристаллическое вещество производного гетероциклиденацетамида |
ES18810263T ES2934508T3 (es) | 2017-05-31 | 2018-05-30 | Cristal de derivado de heterociclidenacetamida |
DK18810263.6T DK3636640T3 (da) | 2017-05-31 | 2018-05-30 | Krystal af heterocyclidenacetamidderivat |
KR1020197034846A KR102576964B1 (ko) | 2017-05-31 | 2018-05-30 | 헤테로시클리덴 아세트아미드 유도체의 결정 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762512775P | 2017-05-31 | 2017-05-31 | |
JP2017-108017 | 2017-05-31 | ||
JP2017108017A JP6230743B1 (ja) | 2017-05-31 | 2017-05-31 | ヘテロシクリデンアセトアミド誘導体の結晶 |
US62/512,775 | 2017-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018221543A1 true WO2018221543A1 (ja) | 2018-12-06 |
Family
ID=60321089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/020634 WO2018221543A1 (ja) | 2017-05-31 | 2018-05-30 | ヘテロシクリデンアセトアミド誘導体の結晶 |
Country Status (13)
Country | Link |
---|---|
US (1) | US10208010B2 (ja) |
EP (1) | EP3636640B1 (ja) |
JP (1) | JP6230743B1 (ja) |
KR (1) | KR102576964B1 (ja) |
CN (1) | CN110831930B (ja) |
CA (1) | CA3059483A1 (ja) |
DK (1) | DK3636640T3 (ja) |
ES (1) | ES2934508T3 (ja) |
HU (1) | HUE061363T2 (ja) |
MX (1) | MX2019014216A (ja) |
PL (1) | PL3636640T3 (ja) |
PT (1) | PT3636640T (ja) |
WO (1) | WO2018221543A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021066144A1 (ja) | 2019-10-04 | 2021-04-08 | 千寿製薬株式会社 | ヘテロシクリデンアセトアミド誘導体含有医薬 |
WO2022210784A1 (ja) | 2021-03-30 | 2022-10-06 | 千寿製薬株式会社 | ヘテロシクリデンアセトアミド誘導体含有懸濁液 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6230743B1 (ja) * | 2017-05-31 | 2017-11-15 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の結晶 |
CN113993858B (zh) * | 2019-04-30 | 2024-05-28 | 北京泰德制药股份有限公司 | 二氨基嘧啶类化合物或其水合物的固体形式及其制备方法和用途 |
WO2024071348A1 (ja) * | 2022-09-29 | 2024-04-04 | 千寿製薬株式会社 | 滅菌処理したヘテロシクリデンアセトアミド誘導体含有懸濁液 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007010383A1 (ja) | 2005-07-22 | 2007-01-25 | Mochida Pharmaceutical Co., Ltd. | 新規なヘテロシクリデンアセトアミド誘導体 |
JP2017108017A (ja) | 2015-12-10 | 2017-06-15 | キヤノン株式会社 | レーザ装置、及びこれを用いた計測装置 |
JP6230743B1 (ja) * | 2017-05-31 | 2017-11-15 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の結晶 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101228131B (zh) * | 2005-07-22 | 2013-01-09 | 持田制药株式会社 | 新的杂环亚基乙酰胺衍生物 |
JP2011201777A (ja) * | 2008-07-23 | 2011-10-13 | Mochida Pharmaceut Co Ltd | 光学活性なヘテロシクリデン−n−アリールアセトアミド誘導体 |
-
2017
- 2017-05-31 JP JP2017108017A patent/JP6230743B1/ja active Active
-
2018
- 2018-05-30 EP EP18810263.6A patent/EP3636640B1/en active Active
- 2018-05-30 ES ES18810263T patent/ES2934508T3/es active Active
- 2018-05-30 CN CN201880035532.5A patent/CN110831930B/zh active Active
- 2018-05-30 WO PCT/JP2018/020634 patent/WO2018221543A1/ja active Application Filing
- 2018-05-30 PT PT188102636T patent/PT3636640T/pt unknown
- 2018-05-30 HU HUE18810263A patent/HUE061363T2/hu unknown
- 2018-05-30 CA CA3059483A patent/CA3059483A1/en active Pending
- 2018-05-30 US US15/993,082 patent/US10208010B2/en active Active
- 2018-05-30 KR KR1020197034846A patent/KR102576964B1/ko active IP Right Grant
- 2018-05-30 MX MX2019014216A patent/MX2019014216A/es unknown
- 2018-05-30 DK DK18810263.6T patent/DK3636640T3/da active
- 2018-05-30 PL PL18810263.6T patent/PL3636640T3/pl unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007010383A1 (ja) | 2005-07-22 | 2007-01-25 | Mochida Pharmaceutical Co., Ltd. | 新規なヘテロシクリデンアセトアミド誘導体 |
JP2017108017A (ja) | 2015-12-10 | 2017-06-15 | キヤノン株式会社 | レーザ装置、及びこれを用いた計測装置 |
JP6230743B1 (ja) * | 2017-05-31 | 2017-11-15 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の結晶 |
Non-Patent Citations (3)
Title |
---|
CATERINA MJSCHUMACHER MATOMINAGA MROSEN TALEVINE JDJULIUS D, NATURE, vol. 389, 1997, pages 816 - 824 |
RASHID MHINOUE MKONDO SKAWASHIMA TBAKOSHI SUEDA H, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 304, 2003, pages 940 - 948 |
SZABO AHELYES ZSANDOR KBITTE APINTER ENEMETH JBANVOLGYI ABOLCSKEI KELEKES KSZOLCSANYI J, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 314, 2005, pages 111 - 119 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021066144A1 (ja) | 2019-10-04 | 2021-04-08 | 千寿製薬株式会社 | ヘテロシクリデンアセトアミド誘導体含有医薬 |
JPWO2021066144A1 (ja) * | 2019-10-04 | 2021-12-02 | 千寿製薬株式会社 | ヘテロシクリデンアセトアミド誘導体含有医薬 |
JP7025094B2 (ja) | 2019-10-04 | 2022-02-24 | 千寿製薬株式会社 | ヘテロシクリデンアセトアミド誘導体含有医薬 |
JP2022065024A (ja) * | 2019-10-04 | 2022-04-26 | 千寿製薬株式会社 | ヘテロシクリデンアセトアミド誘導体含有医薬 |
CN114585357A (zh) * | 2019-10-04 | 2022-06-03 | 千寿制药株式会社 | 含有杂环亚基乙酰胺衍生物的药物 |
JP7248836B2 (ja) | 2019-10-04 | 2023-03-29 | 千寿製薬株式会社 | ヘテロシクリデンアセトアミド誘導体含有医薬 |
WO2022210784A1 (ja) | 2021-03-30 | 2022-10-06 | 千寿製薬株式会社 | ヘテロシクリデンアセトアミド誘導体含有懸濁液 |
JP7175431B1 (ja) * | 2021-03-30 | 2022-11-18 | 千寿製薬株式会社 | ヘテロシクリデンアセトアミド誘導体含有懸濁液 |
JP2023011898A (ja) * | 2021-03-30 | 2023-01-24 | 千寿製薬株式会社 | ヘテロシクリデンアセトアミド誘導体含有懸濁液 |
JP7273235B2 (ja) | 2021-03-30 | 2023-05-12 | 千寿製薬株式会社 | ヘテロシクリデンアセトアミド誘導体含有懸濁液 |
Also Published As
Publication number | Publication date |
---|---|
HUE061363T2 (hu) | 2023-06-28 |
EP3636640A4 (en) | 2021-03-03 |
JP6230743B1 (ja) | 2017-11-15 |
US10208010B2 (en) | 2019-02-19 |
CA3059483A1 (en) | 2018-12-06 |
PL3636640T3 (pl) | 2023-02-27 |
CN110831930B (zh) | 2023-04-28 |
DK3636640T3 (da) | 2022-12-19 |
US20180346436A1 (en) | 2018-12-06 |
RU2019137598A3 (ja) | 2021-07-07 |
KR102576964B1 (ko) | 2023-09-11 |
CN110831930A (zh) | 2020-02-21 |
MX2019014216A (es) | 2020-01-23 |
ES2934508T3 (es) | 2023-02-22 |
JP2018203648A (ja) | 2018-12-27 |
EP3636640B1 (en) | 2022-11-30 |
PT3636640T (pt) | 2022-12-26 |
RU2019137598A (ru) | 2021-06-30 |
EP3636640A1 (en) | 2020-04-15 |
KR20200011943A (ko) | 2020-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6230743B1 (ja) | ヘテロシクリデンアセトアミド誘導体の結晶 | |
JP7174132B2 (ja) | オメカムチブメカルビルの塩及び塩を調製するプロセス | |
JP6381016B2 (ja) | 選択的cdk4/6阻害剤の固体形態 | |
AU2013333953B2 (en) | Multicomponent crystalline system comprising nilotinib and selected co-crystal formers | |
JP2024023383A (ja) | 社会的機能障害の治療方法 | |
WO2022133236A1 (en) | Solid forms of a compound | |
US20220002306A1 (en) | Crystal form of upadacitinib and preparation method and use thereof | |
JP2018527363A (ja) | リナグリプチン結晶形及びこの製造方法 | |
CA2971484C (en) | Polymorphic substance of yonkenafil hydrochloride, preparation method therefor, and composition and use thereof | |
WO2014034626A1 (ja) | N-[2-({2-[(2S)-2-シアノピロリジン-1-イル]-2-オキソエチル}アミノ)-2-メチルプロピル]-2-メチルピラゾロ[1,5-a]ピリミジン-6-カルボキサミドの結晶 | |
RU2779198C2 (ru) | Кристаллическое вещество производного гетероциклиденацетамида | |
WO2020011257A1 (zh) | 一种稠合三环γ-氨基酸衍生物的组合物及其制备 | |
US9981912B2 (en) | Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof | |
EP2649996A1 (en) | Crystalline forms of sartans like telmisartan with beta blockers | |
JP7134983B2 (ja) | テトラヒドロナフチルウレア誘導体の結晶 | |
JP2018048204A (ja) | 4−[2−ジメチルアミノ−1−(1−ヒドロキシシクロヘキシル)エチル]フェニル4−メチルベンゾエートヒドロクロリドの多形体、それらを作製する方法及びそれらの使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 3059483 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20197034846 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2019137598 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018810263 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2018810263 Country of ref document: EP Effective date: 20200102 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |